

## **Plasma glycome reflects low back pain progression and is not predictive of acute-to-chronic pain transition**

Elizaveta E. Elgaeva<sup>1,2</sup>, Irena Trbojević-Akmačić<sup>3</sup>, Ivo Ugrina<sup>3</sup>, Marija Vilaj<sup>3</sup>, Anita Slana<sup>3</sup>, Tea Pribic<sup>3</sup>, Yakov A. Tsepilov<sup>2</sup>, Lennart C. Karssen<sup>4</sup>, Yurii S. Aulchenko<sup>2,4</sup>, Concetta Dagostino<sup>5</sup>, Massimo Allegri<sup>6,7</sup>, Andrea Skelin<sup>8</sup>, Dragan Primorac<sup>8</sup>, Klaas Buyse<sup>9</sup>, Jan Van Zundert<sup>9,10</sup>, Gordan Lauc<sup>3</sup>, Frances M.K. Williams<sup>11</sup>, Maxim B. Freidin<sup>11,\*</sup>

1 – Novosibirsk State University, Novosibirsk, Russia

2 – Institute of Cytology and Genetics, Novosibirsk, Russia

3 – Genos, Glycoscience Research Laboratory, Zagreb, Croatia

4 – PolyOmica, s’-Hertogenbosch, The Netherlands

5 – Department of Medicine and Surgery, University of Parma, Parma, Italy

6 – Pain Management and Neuromodulation Centre, Ensemble Hospitalier de la Côte, Morges, Switzerland

7 - Pain Therapy Service, Policlinico of Monza Hospital, Monza, Italy

8 – St. Catherine Hospital, Zagreb, Croatia

9 – Department of Anesthesiology, Intensive Care, Emergency Medicine and Multidisciplinary Pain Centre, Ziekenhuis Oost Limburg, Genk/Lanaken, Belgium

10 – Department of Anesthesiology and Pain Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands

11 – Department of Twin Research and Genetic Epidemiology, School of Life Course & Population Sciences, King’s College London, London, UK

**\*Corresponding author:** Maxim Freidin, Department of Twin Research and Genetic Epidemiology, School of Life Course & Population Sciences, King’s College London, London, UK; tel. +44 (0) 20 7188 6765; e-mail: [maxim.freydin@kcl.ac.uk](mailto:maxim.freydin@kcl.ac.uk)

**Author contribution:** FMKW, GL, JVZ, DP, MA, YSA, planned the study, oversaw data collection, and developed study design; EEE, MBF, carried out statistical analysis and drafted the manuscript; YAT, LCK, provided computation and analytical support; ITA, IU, MV, AS, TP, carried out glycome analysis; CD, AS, KB, carried out recruitment and sample collection. All co-authors contributed in final manuscript drafting.

**Acknowledgements:** We are grateful to the participants of the study. We also would like to acknowledge Ambreen Tariq, Helena Wells, and Catherine Redshaw for recruiting the study participants as well as the personnel of the following clinical facilities: St Thomas Hospital, Guy's and St Thomas' NHS Trust, London; British School of Osteopathy (since 2017, The University College of Osteopathy), London; Darent Valley Hospital, Dartford and Gravesham NHS Trust, Dartford; Northampton General Hospital Trust, Northampton; Solent NHS Trust, Portsmouth; Brighton and Hove City Primary Care Trust (Benfield Valley Healthcare Hub, Brighton Health and Wellbeing Centre, Charter Medical Centre, Sackville Medical Centre); Brockwood Medical Practice, Betchworth; Sea Road Surgery, Bexhill-on-Sea; Woodbridge Hill Surgery, Guildford; St. Catherine Hospital, Zagreb; Clinical Hospital "Holly Spirit", Special hospital for medical rehabilitation "Krapinske Toplice", Medical School University of Split, Clinical Hospital Split; Anesthesia, Critical Care and Pain Medicine Unit, Department of Medicine and Surgery at University of Parma; and Hospital Oost-Limburg, Maastricht.

**Funding:** This research was supported by the European Commission FP7 "PainOmics" project (contract No. 602736). YAT and EEE were supported by the Russian Science Foundation grant # 22-15-20037 and the Government of the Novosibirsk region. YSA was partially supported by the budget project of the Institute of Cytology and Genetics # FWNR-2022-0020.

**Statements and declarations:** YSA and LCK are the founders and owners of PolyOmics and PolyKnomics, private organizations providing services, research, and development in the field of computational and statistical genomics. GL is the founder and owner of Genos Ltd., a private research organization that specializes in high-throughput glycomic analysis and has several patents in this field. IU, ITA, MV, AS, and TP are employees of Genos Ltd. Other authors declare no competing interests.

**Ethical disclosure:** Ethical approval has been obtained at each respective institution who carried out recruitment and sample collection: National Research Ethics Service Committee London - Westminster (London, UK); Comité Medische Ethiek van Ziekenhuis Oost-Limburg (Genk, Belgium); Comitato Etico per Parma (Parma, Italy); IRCCS Fondazione Policlinico San Matteo (Pavia, Italy); Etički odbor Specijalna bolnica Sv. Katarina (Zagreb, Croatia). Copies of approvals were provided to the European Commission before starting the study. All participants gave informed consent to take part in the study.

**Data sharing statement:** Original data presented in the current study are available through a request to TwinsUK (<https://twinsuk.ac.uk/resources-for-researchers/our-data/>).

## **Abstract**

**Aims:** To investigate if the plasma N-glycome would provide a biomarker of acute-to-chronic low back pain (LBP) transition.

**Patients & Methods:** A prospective longitudinal sample of n = 1,114 individuals enrolled at the first ever episode of LBP and followed-up for three months. Total plasma N-glycome was measured and compared at the baseline and follow-up.

**Results:** Initial pro-inflammatory patterns of plasma N-glycome change to normal levels between baseline and follow-up in those who resolved from LBP, but not in those who remained at pain after three months. Baseline levels of N-glycans were not predictive of the risk of chronic LBP at follow-up.

**Conclusion:** Total plasma N-glycan levels may reflect ongoing inflammation that is aberrant and promotes ongoing pain and chronicity of symptoms.

**Keywords:** chronic back pain, glycome, predictive biomarkers, stratified treatment

## Introduction

Low back pain (LBP) is a common debilitating condition which leads the list of disorders causing disability in much of the world [1]. For the majority of people, the symptoms of LBP are transient; however about 10%-15% develop chronic LBP which is usually defined as LBP lasting for more than three months [2]. It leads to work absenteeism, job loss and long-term disability. In Europe, the costs of chronic LBP are estimated to amount to 1-2% of GDP [3-6]. Risk factors for chronic LBP include age, female sex and raised body mass index, but their relative contribution varies by population [7].

One of the most pressing issues in the field of LBP is our current inability to predict which patients with acute LBP will go on to develop chronic LBP which may be accompanied by disability. The early identification of high-risk patients and stratification into the most suitable treatment groups have been shown to be effective; and the huge economic burden of LBP could be addressed via faster direction of patients to more effective targeted intervention [8]. Several screening tools are used in primary care to stratify LBP patients into targeted treatment subgroups. These screening tools comprise self-report questionnaires that consider physical and psychological characteristics, including pain intensity, functional impairment, catastrophising, anxiety and depression, and predict the risk of persistent pain, disability, recovery, and sick leave duration. The STarT Back Tool (SBT) [9] is one of the most widely used tools of this kind; it allocates patients into low risk group requiring primary care, medium risk group requiring physiotherapy, and high risk group benefiting from a combination of physical and cognitive treatment [10]. SBT and similar tools have been shown to accurately predict the risk of disability and job absenteeism, but their prediction of the development of chronic back pain is rather poor, at 60-70% correct allocation [11].

We hypothesised that combining such a screening tool with serum biomarkers provides a way to improve stratification and prediction of chronic LBP risk. The plasma glycome describes the entire composition of oligosaccharides called glycans attached covalently to proteins and lipids, most

commonly to a nitrogen atom of asparagine (N-glycans) or oxygen atom of serine or threonine (O-glycans). Many inflammatory and immune-mediated diseases, as well as some cancers, are characterised by specific changes in the glycome composition [12-15]. Our own studies provided evidence on association between total plasma and immunoglobulin G (IgG) N-glycome with chronic LBP. We identified that higher risk of chronic LBP is associated with the lack of core fucosylation of IgG [16]. Given that core fucosylation of IgG is a “safety switch” for antibody dependent cell mediated cytotoxicity (ADCC) and that ADCC likely contributes to back pain syndrome and other musculoskeletal manifestations of inflammatory bowel disease [17] we suggested ADCC-driven inflammation as a contributing factor of LBP development. Another potential mechanism is so called “autoimmune pain” caused by IgG-mediated autoimmune response against components of nervous system to which ADCC also contributes [18]. In addition, we demonstrated a pro-inflammatory profile of total plasma N-glycome in chronic LBP patients characterised by the increase in the relative amount of high-branched N-glycan structures, disialylated and trisialylated glycan structures and the decrease of high-mannose glycans and glycans containing bisecting N-acetylglucosamine [19].

Thus, the analysis of glycome may provide important biological and clinically relevant information on the mechanisms of the transition from acute to chronic LBP. Moreover, studies show that changes in glycome profiles may precede the onset of clinical diseases, thus proving glycome as a valuable predictive biomarker. For instance, variation in IgG glycosylation has been shown to precede the onset of rheumatoid arthritis [12,20], type 2 diabetes [21], and hypertension [22].

Herewith, we investigated whether the plasma N-glycome predicts the conversion of acute LBP to chronic LBP using a prospective dataset generated in the framework of the EU FP7 PainOmics project [23,24].

## Material and methods

We prospectively recruited  $n = 1,114$  participants (512 males, 602 females, aged from 16 to 94 with mean age  $51.7 \pm 15.8$ ) [23,24], through clinical centers across Europe: British School of Osteopathy (under auspices of King's College London; KCL, UK), University of Parma (UPR, Italy), San Mateo Hospital (OSM, Italy), St. Catherine Hospital (STCAT, Croatia), and Hospital Oost-Limburg (ZOL, Belgium) (Supplementary table 1). Ethical approval has been obtained at each respective institution, and all participants gave informed consent to take part in the study. Clinical assessment and plasma collection were performed at two time points: at baseline (BL) at the time of their first episode of LBP and follow-up (FU) after three months of conventional treatment. Those who reported ongoing LBP at three months were considered as cases of chronic LBP, while those in whom LBP had resolved were considered controls. Exclusion criteria were: clinically unstable disease, severe psychiatric disorders (apart from mild depression) or mental impairment, recent history (<1 year) of spinal fracture, back pain due to spinal tumour or infection, and pregnancy.

Total plasma N-glycans have been assessed at BL and FU as described elsewhere, with 39 original N-glycan traits measured and recalculated to 14 derived glycan traits [19]. At BL, full set of data (both LBP and glycan levels) was present for 1,085 people, while at FU full set of data was available for 549 participants. For 520 participants, information about both LBP and glycan profiles was present at both time points (Supplementary Table 2; Figure 1).

We addressed three questions (Figure 2):

- Q1: Is there difference in total plasma N-glycan levels between cases and controls at FU? This is equivalent to a cross-sectional comparison carried out earlier [19] and aimed to assess validity of our dataset;

- Q2: Is there difference in glycan levels between BL and FU for cases and controls? The answer to this question would inform us about dynamics of plasma N-glycome during convalescence and persistence of the disease.
- Q3: Is there difference between cases and controls (as established at FU stage) at BL stage? This would inform us if plasma glycome can serve as predictive biomarker.

For each cohort, glycan profiles were corrected for age, sex, and body mass index via residuals followed by the inverse rank-transformation to normality for the glycan traits to achieve  $N [0,1]$ . To address Q1 and Q3 we carried out linear regression considering the case/control status as an explanatory variable and the glycan level as a dependent variable. The results from all cohorts were meta-analyzed with Z-based method using metafor v2.1.0 package for R (<https://cran.r-project.org/web/packages/metafor/metafor.pdf>). To address Q2, we carried out a paired t-test followed by meta-analysis using metap v1.1 package for R (<https://cran.r-project.org/web/packages/metap/index.html>). The statistical significance threshold with correction for multiple testing was set at  $p < 0.05/14 \approx 0.004$ . All the analyses were run in R programming language v. 3.5.3 and 3.6.1 in RStudio.

## Results

None of the glycan traits was statistically significantly associated with chronic LBP when comparing cases and controls and FU (Q1) and adjusting for multiple testing; however, the direction and the magnitude of the effects were concordant with the results obtained by us previously in a bigger sample [19] (Table 1). Three glycan traits (neutral, S0; monogalactosylated, G1; and high-mannose glycans, HM) achieved nominal significance ( $p < 0.05$ ).

Addressing Q2, we found statistically significant alteration in plasma glycome between BL and FU in controls, but not in cases (Table 2). The changes concerned levels of low- and high-branching glycans, di- and trigalactosylated glycans (LB, HB, G2, and G3, respectively). Changes with nominal significance ( $p < 0.05$ ) were identified for neutral (non-sialylated), trisialylated, monogalactosylated glycans, and bisecting glycans (S0, S3, G1, B, respectively). Levels of LB were found to increase at FU, while levels of HB, and G3 decreased at FU compared to BL. Notably, the direction of changes in levels of G2 was not consistent between the cohorts, and most significant results were observed for STCAT with a very small sample size ( $n = 2$ ); thus, this result must be treated with caution. Considering results of the case-control comparisons at FU (Table 1) and these results, it can be noted that in controls changes are directed towards the plasma N-glycome profile seen in healthy individuals. In particular, LB levels while being decreased in LBP change towards the increase from BL to FU in controls, i.e. individuals whose pain resolved in conventional treatment. At the same time, HB and S3 levels while being increased in LBP change towards the decrease from BL to FU. These findings demonstrate that plasma N-glycome changes along with the process of convalescence towards a “healthy” non-inflammatory profile. In accordance with that, no such changes are seen in cases of chronic LBP, thus assuming the persistence of ongoing inflammation.

Finally, addressing the Q3, we did not find statistically significant differences in plasma N-glycome levels between cases and controls at BL (Table 3).

## Discussion

The current study aimed to determine whether plasma N-glycome is a predictive biomarker of risk of chronic LBP during an episode of acute severe back pain. We confirmed an earlier observed trend [19] towards the decrease of S0, G1, and HM in patients with chronic LBP, found changes in glycome profile



between BL and FU in controls, but not cases of chronic LBP, and did not find differences in glycome profile between cases and controls at BL.

Our findings suggest that plasma N-glycome does not predict transition between acute and chronic LBP; however, it reflects the dynamics of the condition: remains stable if inflammation is progressing and reverses to a normal state during convalescence. This finding corroborates with the results of a recent study of transcriptomic changes in immune cells of those who resolved from LBP after three months of conventional treatment, but not among those who did not resolve [25]. This transcriptomic study identified upregulated neutrophil-driven resolution of inflammation associated with convalescence.

As proven by clinical tools, such as SBT, predicting risks of chronic LBP and disability facilitates treatment and exhibits economic benefits [8-10]. The current study did not provide evidence that total plasma N-glycan levels at LBP onset would be predictive of future chronic LBP, thus warranting to investigate other biomarkers. Among promising options is a polygenic risk score (PRS) that summarises the effects of multiple genetic factors across the genome to predict disease risk [26]. Upon calculation of their PRS, each individual may be classified as high or low risk if their score falls into upper or lower quintile of the PRS distribution. A public resource – PRS atlas – collecting PRS for various diseases has been compiled in response to public and clinical interest in the field [27]. There is now good evidence that this approach works in clinical settings. For instance, PRS added to conventional risk factors could potentially prevent 7% additional cardiovascular events compared to conventional risk prediction [28]. Bronchodilator response to asthma medicine could be predicted by a pharmacogenetic PRS, thereby avoiding unnecessary and potentially dangerous trials of ineffective medicines [29]. PRS predicts more severe cases of inflammatory bowel disease [30]. To the best of our knowledge, apart from our own pilot attempt focusing on glycome-based GWAS [31], no PRS for chronic LBP has been published despite the availability of high-scale GWAS for this trait [32-34], let alone any attempts to combine PRS and clinical tools such as SBT.

Our study limitation is heterogeneity between the study centres. Another limitation is the lack of replication in an independent cohort. However, consistence with the previous study [19] adds confidence in validity of our findings.

## References

- [1] Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, *Lancet* 390 (2017) 1211-1259. 10.1016/S0140-6736(17)32154-2.
- [2] L. Manchikanti, V. Singh, F.J. Falco, R.M. Benyamin, J.A. Hirsch, Epidemiology of low back pain in adults, *Neuromodulation* 17 Suppl 2 (2014) 3-10. 10.1111/ner.12018.
- [3] C.M. Wenig, C.O. Schmidt, T. Kohlmann, B. Schweikert, Costs of back pain in Germany, *Eur J Pain* 13 (2009) 280-286. 10.1016/j.ejpain.2008.04.005.
- [4] M. Gore, A. Sadosky, B.R. Stacey, K.S. Tai, D. Leslie, The burden of chronic low back pain: clinical comorbidities, treatment patterns, and health care costs in usual care settings, *Spine (Phila Pa 1976)* 37 (2012) E668-677. 10.1097/BRS.0b013e318241e5de.
- [5] N. Maniadakis, A. Gray, The economic burden of back pain in the UK, *Pain* 84 (2000) 95-103.
- [6] J. Hong, C. Reed, D. Novick, M. Happich, Costs associated with treatment of chronic low back pain: an analysis of the UK General Practice Research Database, *Spine (Phila Pa 1976)* 38 (2013) 75-82. 10.1097/BRS.0b013e318276450f.
- [7] J.B. Taylor, A.P. Goode, S.Z. George, C.E. Cook, Incidence and risk factors for first-time incident low back pain: a systematic review and meta-analysis, *Spine J* 14 (2014) 2299-2319. 10.1016/j.spinee.2014.01.026.
- [8] J.C. Hill, D.G. Whitehurst, M. Lewis, S. Bryan, K.M. Dunn, N.E. Foster, K. Konstantinou, C.J. Main, E. Mason, S. Somerville, G. Sowden, K. Vohora, E.M. Hay, Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial, *Lancet* 378 (2011) 1560-1571. 10.1016/S0140-6736(11)60937-9.
- [9] J.C. Hill, K.M. Dunn, M. Lewis, R. Mullis, C.J. Main, N.E. Foster, E.M. Hay, A primary care back pain screening tool: identifying patient subgroups for initial treatment, *Arthritis Rheum* 59 (2008) 632-641. 10.1002/art.23563.
- [10] E.M. Hay, K.M. Dunn, J.C. Hill, M. Lewis, E.E. Mason, K. Konstantinou, G. Sowden, S. Somerville, K. Vohora, D. Whitehurst, C.J. Main, A randomised clinical trial of subgrouping and targeted treatment for low back pain compared with best current care. The STarT Back Trial Study Protocol, *BMC Musculoskeletal Disord* 9 (2008) 58. 10.1186/1471-2474-9-58.
- [11] E.L. Karran, J.H. McAuley, A.C. Traeger, S.L. Hillier, L. Grabherr, L.N. Russek, G.L. Moseley, Can screening instruments accurately determine poor outcome risk in adults with recent onset low back pain? A systematic review and meta-analysis, *BMC Med* 15 (2017) 13. 10.1186/s12916-016-0774-4.
- [12] A. Ercan, J. Cui, D.E. Chatterton, K.D. Deane, M.M. Hazen, W. Brintnell, C.I. O'Donnell, L.A. Derber, M.E. Weinblatt, N.A. Shadick, D.A. Bell, E. Cairns, D.H. Solomon, V.M. Holers, P.M. Rudd, D.M. Lee, Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis, *Arthritis Rheum* 62 (2010) 2239-2248. 10.1002/art.27533.
- [13] Y. Rombouts, E. Ewing, L.A. van de Stadt, M.H. Selman, L.A. Trouw, A.M. Deelder, T.W. Huizinga, M. Wuhler, D. van Schaardenburg, R.E. Toes, H.U. Scherer, Anti-citrullinated protein antibodies acquire a

pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis, *Ann Rheum Dis* 74 (2015) 234-241. 10.1136/annrheumdis-2013-203565.

[14] I. Trbojevic-Akmacic, N.T. Ventham, E. Theodoratou, F. Vuckovic, N.A. Kennedy, J. Kristic, E.R. Nimmo, R. Kalla, H. Drummond, J. Stambuk, M.G. Dunlop, M. Novokmet, Y. Aulchenko, O. Gornik, H. Campbell, M. Pucic Bakovic, J. Satsangi, G. Lauc, I.-B. Consortium, Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome, *Inflamm Bowel Dis* 21 (2015) 1237-1247. 10.1097/MIB.0000000000000372.

[15] F. Vuckovic, J. Kristic, I. Gudelj, M. Teruel, T. Keser, M. Pezer, M. Pucic-Bakovic, J. Stambuk, I. Trbojevic-Akmacic, C. Barrios, T. Pavic, C. Menni, Y. Wang, Y. Zhou, L. Cui, H. Song, Q. Zeng, X. Guo, B.A. Pons-Estel, P. McKeigue, A. Leslie Patrick, O. Gornik, T.D. Spector, M. Harjacek, M. Alarcon-Riquelme, M. Molokhia, W. Wang, G. Lauc, Association of Systemic Lupus Erythematosus With Decreased Immunosuppressive Potential of the IgG Glycome, *Arthritis Rheumatol* 67 (2015) 2978-2989. 10.1002/art.39273.

[16] M.B. Freidin, T. Keser, I. Gudelj, J. Stambuk, D. Vucenovic, M. Allegri, T. Pavic, M. Simurina, S.M. Fabiane, G. Lauc, F.M. Williams, The Association Between Low Back Pain and Composition of IgG Glycome, *Sci Rep* 6 (2016) 26815. 10.1038/srep26815.

[17] T. Sheth, C.S. Pitchumoni, K.M. Das, Musculoskeletal manifestations in inflammatory bowel disease: a revisit in search of immunopathophysiological mechanisms, *J Clin Gastroenterol* 48 (2014) 308-317. 10.1097/MCG.0000000000000067.

[18] M. Xu, D.L.H. Bennett, L.A. Querol, L.J. Wu, S.R. Irani, J.C. Watson, S.J. Pittock, C.J. Klein, Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies, *J Neurol Neurosurg Psychiatry* 91 (2020) 177-188. 10.1136/jnnp-2018-318556.

[19] I. Trbojevic-Akmacic, F. Vuckovic, M. Vilaj, A. Skelin, L.C. Karssen, J. Kristic, J. Juric, A. Momcilovic, J. Simunovic, M. Mangino, M. De Gregori, M. Marchesini, C. Dagostino, J. Stambuk, M. Novokmet, R. Rauck, Y.S. Aulchenko, D. Primorac, L. Kapural, K. Buyse, D. Mesotten, F.M.K. Williams, J. van Zundert, M. Allegri, G. Lauc, Plasma N-glycome composition associates with chronic low back pain, *Biochim Biophys Acta Gen Subj* 1862 (2018) 2124-2133. 10.1016/j.bbagen.2018.07.003.

[20] I. Gudelj, P.P. Salo, I. Trbojevic-Akmacic, M. Albers, D. Primorac, M. Perola, G. Lauc, Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10years of follow-up, *Biochim Biophys Acta Mol Basis Dis* 1864 (2018) 2034-2039. 10.1016/j.bbadis.2018.03.018.

[21] T. Keser, I. Gornik, F. Vuckovic, N. Selak, T. Pavic, E. Lukic, I. Gudelj, H. Gasparovic, B. Biocina, T. Tilin, A. Wennerstrom, S. Mannisto, V. Salomaa, A. Havulinna, W. Wang, J.F. Wilson, N. Chaturvedi, M. Perola, H. Campbell, G. Lauc, O. Gornik, Increased plasma N-glycome complexity is associated with higher risk of type 2 diabetes, *Diabetologia* 60 (2017) 2352-2360. 10.1007/s00125-017-4426-9.

[22] D. Kifer, P. Louca, A. Cvetko, H. Deris, A. Cindric, H. Grallert, A. Peters, O. Polasek, O. Gornik, M. Mangino, T.D. Spector, A.M. Valdes, S. Padmanabhan, C. Gieger, G. Lauc, C. Menni, N-glycosylation of immunoglobulin G predicts incident hypertension, *J Hypertens* 39 (2021) 2527-2533. 10.1097/HJH.0000000000002963.

[23] M. Allegri, M. De Gregori, C.E. Minella, C. Klersy, W. Wang, M. Sim, C. Gieger, J. Manz, I.K. Pemberton, J. MacDougall, F.M. Williams, J. Van Zundert, K. Buyse, G. Lauc, I. Gudelj, D. Primorac, A. Skelin, Y.S. Aulchenko, L.C. Karssen, L. Kapural, R. Rauck, G. Fanelli, O.G. Pain, 'Omics' biomarkers associated with chronic low back pain: protocol of a retrospective longitudinal study, *BMJ Open* 6 (2016) e012070. 10.1136/bmjopen-2016-012070.

[24] C. Dagostino, M. De Gregori, C. Gieger, J. Manz, I. Gudelj, G. Lauc, L. Divizia, W. Wang, M. Sim, I.K. Pemberton, J. MacDougall, F. Williams, J. Van Zundert, D. Primorac, Y. Aulchenko, L. Kapural, M. Allegri, G. PainOmics, Validation of standard operating procedures in a multicenter retrospective study to

identify -omics biomarkers for chronic low back pain, PLoS One 12 (2017) e0176372.

10.1371/journal.pone.0176372.

[25] M. Parisien, L.V. Lima, C. Dagostino, N. El-Hachem, G.L. Drury, A.V. Grant, J. Huising, V. Verma, C.B. Meloto, J.R. Silva, G.G.S. Dutra, T. Markova, H. Dang, P.A. Tessier, G.D. Slade, A.G. Nackley, N. Ghasemlou, J.S. Mogil, M. Allegri, L. Diatchenko, Acute inflammatory response via neutrophil activation protects against the development of chronic pain, Sci Transl Med 14 (2022) eabj9954.

10.1126/scitranslmed.abj9954.

[26] N. Chatterjee, J. Shi, M. Garcia-Closas, Developing and evaluating polygenic risk prediction models for stratified disease prevention, Nat Rev Genet 17 (2016) 392-406. 10.1038/nrg.2016.27.

[27] T.G. Richardson, S. Harrison, G. Hemani, G. Davey Smith, An atlas of polygenic risk score associations to highlight putative causal relationships across the human phenome, Elife 8 (2019).

10.7554/eLife.43657.

[28] L. Sun, L. Pennells, S. Kaptoge, C.P. Nelson, S.C. Ritchie, G. Abraham, M. Arnold, S. Bell, T. Bolton, S. Burgess, F. Dudbridge, Q. Guo, E. Sofianopoulou, D. Stevens, J.R. Thompson, A.S. Butterworth, A. Wood, J. Danesh, N.J. Samani, M. Inouye, E. Di Angelantonio, Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses, PLoS Med 18 (2021) e1003498.

10.1371/journal.pmed.1003498.

[29] J.E. Sordillo, S.M. Lutz, M.J. McGeachie, J. Lasky-Su, S.T. Weiss, J.C. Celedon, A.C. Wu, Pharmacogenetic Polygenic Risk Score for Bronchodilator Response in Children and Adolescents with Asthma: Proof-of-Concept, J Pers Med 11 (2021). 10.3390/jpm11040319.

[30] G.B. Chen, S.H. Lee, G.W. Montgomery, N.R. Wray, P.M. Visscher, R.B. Gearry, I.C. Lawrance, J.M. Andrews, P. Bampton, G. Mahy, S. Bell, A. Walsh, S. Connor, M. Sparrow, L.M. Bowdler, L.A. Simms, K. Krishnaprasad, I.B.D.G.C. International, G.L. Radford-Smith, G. Moser, Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method, BMC Med Genet 18 (2017) 94. 10.1186/s12881-017-0451-2.

[31] M. Freidin, Y. Aulchenko, G. Lauc, F. Williams, Using glycome-based polygenic risk score to predict risk of back pain, The Society for Back Pain Research (SBPR) 2018 Meeting, Orthopaedic Proceedings, Groningen, The Netherlands, 2018.

[32] M.B. Freidin, Y.A. Tsepilov, M. Palmer, L.C. Karssen, P. Suri, Y.S. Aulchenko, F.M.K. Williams, C.M.W. Group, Insight into the genetic architecture of back pain and its risk factors from a study of 509,000 individuals, Pain 160 (2019) 1361-1373. 10.1097/j.pain.0000000000001514.

[33] M.B. Freidin, Y.A. Tsepilov, I.B. Stanaway, W. Meng, C. Hayward, B.H. Smith, S. Khoury, M. Parisien, A. Bortsov, L. Diatchenko, S. Borte, B.S. Winsvold, B.M. Brumpton, J.A. Zwart, Y.S. Aulchenko, P. Suri, F.M.K. Williams, H.A.-I. Pain, Sex- and age-specific genetic analysis of chronic back pain, Pain 162 (2021) 1176-1187. 10.1097/j.pain.0000000000002100.

[34] P. Suri, M.R. Palmer, Y.A. Tsepilov, M.B. Freidin, C.G. Boer, M.S. Yau, D.S. Evans, A. Gelemanovic, T.M. Bartz, M. Nethander, L. Arbeeva, L. Karssen, T. Neogi, A. Campbell, D. Mellstrom, C. Ohlsson, L.M. Marshall, E. Orwoll, A. Uitterlinden, J.I. Rotter, G. Lauc, B.M. Psaty, M.K. Karlsson, N.E. Lane, G.P. Jarvik, O. Polasek, M. Hochberg, J.M. Jordan, J.B.J. Van Meurs, R. Jackson, C.M. Nielson, B.D. Mitchell, B.H. Smith, C. Hayward, N.L. Smith, Y.S. Aulchenko, F.M.K. Williams, Genome-wide Meta-analysis of 158,000 Individuals of European Ancestry Identifies Three Loci Associated with Chronic Back Pain, (2018).

10.1101/244483.

## Figure legends

**Figure 1 – Flowchart of patients’ availability.** More details are provided in Supplementary table 2.

**Figure 2 - The analysis pipeline.** The figure outlines the research questions addressed as well as the design of the corresponding statistical comparisons

**Table 1 – Comparisons of glycan levels at FU between chronic LBP cases and controls**

Trait	Current study			Previous study [19]	
	Effect (SE)	p-value	I <sup>2</sup> , %	Effect (SE)	p-value
LB	-0.104 (0.083)	0.213	0	-0.247 (0.049)	5.1e-7
HB	0.108 (0.085)	0.203	0	0.223 (0.049)	6.3e-6
<b>S0</b>	<b>-0.201 (0.089)</b>	<b>0.024</b>	<b>42.3</b>	<b>-0.356 (0.049)</b>	<b>4.2e-13</b>
S1	0.046 (0.087)	0.596	0	-0.012 (0.049)	0.803
S2	0.176 (0.091)	0.054	54.6	0.254 (0.049)	2.8e-7
S3	0.067 (0.086)	0.422	0	0.235 (0.050)	2.3e-6
S4	0.072 (0.086)	0.405	15.8	0.057 (0.050)	0.252
G0	-0.132 (0.089)	0.137	31.9	-0.312 (0.044)	1.9e-12
<b>G1</b>	<b>-0.215 (0.090)</b>	<b>0.016</b>	<b>41.5</b>	<b>-0.330 (0.049)</b>	<b>1.6e-11</b>
G2	0.132 (0.090)	0.140	60.9	0.179 (0.048)	1.9e-4
G3	0.132 (0.086)	0.125	0	0.182 (0.048)	1.7e-4
G4	-0.017 (0.085)	0.839	0	0.128 (0.048)	7.4e-3
<b>HM</b>	<b>-0.179 (0.087)</b>	<b>0.039</b>	<b>34.5</b>	<b>-0.219 (0.046)</b>	<b>1.7e-6</b>
B	-0.149 (0.088)	0.090	0	-0.281 (0.049)	8.2e-9

**Legend to table 1:**

LB – low-branching N-glycans, HB – high-branching N-glycans, S0 – neutral or non-sialylated N-glycans, S1 – monosialylated N-glycans, S2 – disialylated N-glycans, S3 – trisialylated N-glycans, S4 – tetrasialylated N-glycans, G0 – non-galactosylated N-glycans, G1 – monogalactosylated N-glycans, G2 – digalactosylated N-glycans, G3 – trigalactosylated N-glycans, G4 – tetragalactosylated N-glycans, HM – high-mannose N-glycans, B – bisecting N-acetylglucosamine containing N-glycans. I<sup>2</sup> – statistics of heterogeneity across meta-analyzed cohorts. Results passing the nominal significance threshold of  $p < 0.05$  in the current study are written in bold. Statistical significance threshold was set at  $p < 0.004$  in the current study.

**Table 2 – Association between glycan levels in cases of chronic LBP and controls**

Trait	Group	Controls			Cases		
		t	df	p	t	df	p
LB	KCL	-1.525	83	0.131	0.169	90	0.866
	OSM	-0.368	15	0.718	0.179	15	0.861
	STCAT	-1.714	2	0.229	-0.612	18	0.548
	UPR	-4.567	122	1.19E-05	-1.497	138	0.137
	ZOL	-	-	-	0.330	27	0.744
	Meta-analysis	-	-	<b>1.83E-04</b>	-	-	0.784
HB	KCL	1.249	83	0.215	-0.437	90	0.663
	OSM	0.879	15	0.393	-0.487	15	0.633
	STCAT	2.384	2	0.140	-0.015	18	0.988
	UPR	4.222	122	4.69E-05	2.437	138	0.016
	ZOL	-	-	-	0.462	27	0.648
	Meta-analysis	-	-	<b>3.43E-04</b>	-	-	0.366
S0	KCL	-0.795	83	0.429	1.611	90	0.111
	OSM	-2.172	15	0.046	-0.268	15	0.793
	STCAT	-0.466	2	0.687	-0.601	18	0.555
	UPR	-2.350	122	0.020	1.146	138	0.254
	ZOL	-	-	-	-0.052	27	0.959
	Meta-analysis	-	-	<b>0.037</b>	-	-	0.545
S1	KCL	-0.300	83	0.765	0.345	90	0.731
	OSM	-0.051	15	0.960	1.155	15	0.266
	STCAT	-1.457	2	0.282	-1.490	18	0.154
	UPR	-0.182	122	0.856	-2.029	138	0.044
	ZOL	-	-	-	0.339	27	0.737
	Meta-analysis	-	-	0.902	-	-	0.180
S2	KCL	0.573	83	0.568	-1.809	90	0.074
	OSM	3.038	15	0.008	-0.011	15	0.991
	STCAT	-0.105	2	0.926	0.978	18	0.341
	UPR	1.130	122	0.261	-1.514	138	0.132
	ZOL	-	-	-	0.099	27	0.922
	Meta-analysis	-	-	0.094	-	-	0.314
S3	KCL	0.729	83	0.468	-0.845	90	0.400
	OSM	1.224	15	0.240	-0.821	15	0.424
	STCAT	2.344	2	0.144	0.006	18	0.996
	UPR	3.244	122	0.002	2.248	138	0.026
	ZOL	-	-	-	0.221	27	0.827
	Meta-analysis	-	-	<b>0.007</b>	-	-	0.340
S4	KCL	2.199	83	0.031	0.995	90	0.322
	OSM	-0.212	15	0.835	0.196	15	0.847
	STCAT	2.252	2	0.153	-0.603	18	0.554
	UPR	1.037	122	0.302	2.756	138	0.007
	ZOL	-	-	-	0.317	27	0.754

	Meta-analysis	-	-	0.096	-	-	0.157
G0	KCL	-1.497	83	0.138	1.742	90	0.085
	OSM	-1.931	15	0.073	-0.565	15	0.580
	STCAT	-0.275	2	0.809	0.001	18	0.999
	UPR	-1.669	122	0.098	1.625	138	0.107
	ZOL	-	-	-	-0.071	27	0.944
	Meta-analysis	-	-	0.075	-	-	0.388
G1	KCL	-0.763	83	0.448	1.415	90	0.161
	OSM	-2.853	15	0.012	-0.239	15	0.814
	STCAT	-0.308	2	0.787	-0.563	18	0.580
	UPR	-2.340	122	0.021	1.129	138	0.261
	ZOL	-	-	-	-0.008	27	0.993
	Meta-analysis	-	-	<b>0.017</b>	-	-	0.643
G2	KCL	-0.069	83	0.945	-1.473	90	0.144
	OSM	3.379	15	0.004	-0.110	15	0.914
	STCAT	-17.404	2	0.003	-0.247	18	0.808
	UPR	-1.023	122	0.308	-3.274	138	0.001
	ZOL	-	-	-	0.105	27	0.917
	<b>Meta-analysis</b>	-	-	<b>0.002</b>	-	-	0.057
G3	KCL	0.701	83	0.485	-0.545	90	0.587
	OSM	0.407	15	0.690	-0.696	15	0.497
	STCAT	2.690	2	0.115	0.177	18	0.861
	UPR	5.307	122	5.06E-07	2.041	138	0.043
	ZOL	-	-	-	1.566	27	0.129
	Meta-analysis	-	-	<b>2.16E-05</b>	-	-	0.216
G4	KCL	1.777	83	0.079	0.009	90	0.993
	OSM	0.372	15	0.715	-0.375	15	0.713
	STCAT	-1.374	2	0.303	-0.647	18	0.526
	UPR	-1.232	122	0.220	1.678	138	0.096
	ZOL	-	-	-	-1.372	27	0.181
	Meta-analysis	-	-	0.193	-	-	0.433
HM	KCL	-1.500	83	0.137	0.914	90	0.363
	OSM	-1.314	15	0.209	-0.995	15	0.335
	STCAT	-0.113	2	0.921	0.494	18	0.627
	UPR	-1.188	122	0.237	1.697	138	0.092
	ZOL	-	-	-	0.040	27	0.968
	Meta-analysis	-	-	0.255	-	-	0.442
B	KCL	-1.525	83	0.131	1.936	90	0.056
	OSM	-1.991	15	0.065	-0.277	15	0.786
	STCAT	-0.833	2	0.492	-1.228	18	0.235
	UPR	-2.502	122	0.014	0.817	138	0.415
	ZOL	-	-	-	-0.593	27	0.558
	Meta-analysis	-	-	<b>0.012</b>	-	-	0.281

**Legend to table 2:**



LB – low-branching N-glycans, HB – high-branching N-glycans, S0 – neutral or non-sialylated N-glycans, S1 – monosialylated N-glycans, S2 – disialylated N-glycans, S3 – trisialylated N-glycans, S4 – tetrasialylated N-glycans, G0 – non-galactosylated N-glycans, G1 – monogalactosylated N-glycans, G2 – digalactosylated N-glycans, G3 – trigalactosylated N-glycans, G4 – tetragalactosylated N-glycans, HM – high-mannose N-glycans, B – bisecting N-acetylglucosamine containing N-glycans. I2 – statistics of heterogeneity across meta-analyzed cohorts. Matched-pairs t-test was applied followed by meta-analysis of p-values using Fisher's combined p-value approach. Negative t-statistics means glycan levels at BL were lower than at the FU; positive t-statistics means glycan levels at BL were higher than at the FU. Results passing the nominal significance threshold of  $p < 0.05$  in the current study are written in bold. Statistical significance threshold was set at  $p < 0.004$  in the current study.


**Table 3 – Association between glycan levels at BL and chronic LBP**

Trait	Effect size (SE)	p-value	I <sup>2</sup> , %
LB	0.006 (0.066)	0.930	0
HB	-0.002 (0.067)	0.976	0
S0	0.021 (0.063)	0.742	25.2
S1	-0.046 (0.066)	0.484	0
S2	0.003 (0.064)	0.965	36.3
S3	0.010 (0.067)	0.881	0
S4	0.003 (0.065)	0.966	0
G0	0.030 (0.064)	0.636	63.2
G1	-0.013 (0.064)	0.837	20.4
G2	-0.008 (0.064)	0.904	59.7
G3	-0.016 (0.067)	0.814	0
G4	0.021 (0.066)	0.750	50.7
HM	0.033 (0.066)	0.619	0
B	0.020 (0.067)	0.764	31.2

**Legend to table 3:**

LB – low-branching N-glycans, HB – high- branching N-glycans, S0 – neutral or non-sialylated N-glycans, S1 – monosialylated N-glycans, S2 – disialylated N-glycans, S3 – trisialylated N-glycans, S4 – tetrasialylated N-glycans, G0 – non-galactosylated N-glycans, G1 – monogalactosylated N-glycans, G2 – digalactosylated N-glycans, G3 – trigalactosylated N-glycans, G4 – tetragalactosylated N-glycans, HM – high-mannose N-glycans, B – bisecting N-acetylglucosamine containing N-glycans. I<sup>2</sup> – statistics of heterogeneity across meta-analyzed cohorts. Statistical significance threshold was set at  $p < 0.004$ .

### Total plasma N-glycome profile



Total N = 1,114 have BP  
status info at FU and glycan  
profile at some time point

At which time  
point glycan  
profile is  
available?

At BL

**N = 1,085**  
(690 CBP controls,  
395 CBP cases)  
Used to answer Q3

Both at BL and FU

**N = 520**  
(227 CBP controls, 293 CBP  
cases)  
Used to answer Q2

At FU

**N = 549**  
(235 CBP controls,  
314 CBP cases)  
Used to answer Q1